The Study at a Glance
Published in World of Medicine and Biology · 2024
Title
Electro-Photonic Emission Analysis in Patients With COPD
Institution
Lithuanian University of Health Sciences
Design
Case-control comparison
Sample
21 COPD patients + 85 healthy controls
In This Guide
Why COPD Is a Perfect Test Case for GDV
Chronic Obstructive Pulmonary Disease isn't just a lung problem. It's a whole-body disease that happens to center on the lungs. COPD damages the airways and air sacs, making breathing progressively harder — but its effects ripple outward into the cardiovascular system, the immune system, metabolism, and even mental health.
This makes it a fascinating test case for GDV technology. If Bio-Well's fingertip emissions are genuinely capturing systemic physiological information — not just random noise — then a multi-system disease like COPD should produce distinctly different emission patterns compared to healthy individuals. That's exactly what the Lithuanian researchers set out to test.
3rd
Leading cause of death globally
3.2M
Deaths per year (WHO, 2024)
80%
Have at least one comorbidity
Multi
System disease — perfect GDV test
Source: WHO fact sheet on COPD (2024). who.int →
What the Researchers Did
Researchers at the Lithuanian University of Health Sciences — one of the Baltic states' premier medical institutions — designed a straightforward case-control study. They scanned two groups with the same EPI/GDV device and compared the emission patterns:
Study Design
21
COPD Patients
Diagnosed with chronic obstructive pulmonary disease. Described as polymorbid — meaning they had COPD plus additional comorbidities, as is typical for the disease.
85
Healthy Controls
Functionally healthy respondents without COPD or significant chronic conditions. Served as the comparison baseline.
The elegance of the study design is its simplicity: same device, same protocol, same analysis software. The only variable is the health status of the participants. If the GDV data shows statistically significant differences between the groups, it suggests the technology is detecting real physiological distinctions.
Interactive: What the Data Revealed
Tap each finding to see what the researchers discovered when they compared COPD patients' emission patterns to healthy controls:
The Polymorbidity Factor
Here's something that makes this study both more interesting and more complicated. The COPD patients in the study weren't just COPD patients — they were described as polymorbid, meaning they had COPD alongside other chronic conditions.
This is actually realistic. In clinical practice, COPD rarely travels alone. The WHO notes that COPD patients commonly have cardiovascular disease, diabetes, osteoporosis, depression, and metabolic syndrome alongside their lung condition. A Lithuanian national database study of over 321,000 patients confirmed that the vast majority of COPD patients have multiple comorbidities.
The Double-Edged Sword
Using polymorbid COPD patients makes the study more clinically realistic — because that's what real COPD patients look like. But it also makes it harder to attribute the GDV differences specifically to COPD versus the combined burden of multiple diseases. The emission patterns may reflect the total disease burden rather than COPD alone.
This is an important nuance. The study tells us that people with a cluster of chronic diseases centered on COPD have measurably different emission patterns from healthy people. It doesn't tell us — and doesn't claim to tell us — whether GDV can distinguish COPD from other chronic conditions.
How This Fits the Bigger Picture
This COPD study is the third clinical study we've explored in this series. When you look at all three together, a consistent pattern emerges:
| Study | Condition | GDV Finding | Day |
|---|---|---|---|
| Bhat et al., 2016 | Diabetes | Pancreas + kidney sectors correlated with blood sugar in prediabetics | 15 |
| Cioca et al., 2004 | Autonomic balance | GDV Stress Index correlated with LF/HF ratio (r = 0.85) | 16 |
| Lithuanian U., 2024 | COPD | Respiratory, cardiovascular, and stress parameters all differed from healthy | 17 |
The thread connecting all three: GDV/EPI parameters consistently differentiate between healthy and unhealthy states across different disease types, different populations, and different research teams. No single study proves the technology — but the pattern of consistent, physiologically plausible findings across independent studies is building a meaningful body of evidence.
What the Study Can't Tell Us
Small COPD group (n=21)
Twenty-one COPD patients is a pilot-scale sample. While the healthy control group (85) was reasonably sized, the disease group needs to be larger for robust conclusions. Studies with 100+ COPD patients would strengthen the findings considerably.
Polymorbidity confound
Because the COPD patients had multiple conditions, the emission differences could reflect the combined burden rather than COPD specifically. A study comparing "COPD only" patients with "COPD + comorbidities" would help isolate the COPD signal.
No severity stratification
COPD is classified into stages (GOLD 1–4) based on lung function. This study doesn't report whether GDV differences correlated with disease severity. Future studies could examine whether emission patterns track with FEV1 (the standard lung function metric).
Single center
All participants came from the Lithuanian University of Health Sciences. While this ensures consistent methodology, it means the results haven't yet been replicated in other clinical settings or populations.
The honest bottom line: This study adds another data point to the growing body of GDV clinical evidence — this time from a European university medical center, with a disease that the WHO ranks as the third leading cause of death globally. The findings are physiologically plausible and consistent with the clinical characteristics of COPD. But like all pilot-scale studies, it needs replication with larger samples before drawing definitive conclusions.
Explore the full evidence base
400+ published studies are indexed in the IUMAB research database.
Sources Cited in This Article
- "Electro-Photonic Emission Analysis In Patients With Chronic Obstructive Pulmonary Disease." Lithuanian University of Health Sciences. World of Medicine and Biology, 2024. Referenced on Bio-Well Science page →
- WHO Fact Sheet: Chronic Obstructive Pulmonary Disease (COPD). Updated 2024. who.int →
- "Epidemiology of COPD Comorbidities in Lithuanian National Database: A Cluster Analysis." Int J Environ Res Public Health. 2022;19(2):970. 321,297 patients analyzed. PMC8775709 →
- Cioca GH, Giacomoni P, Rein G. "A Correlation Between GDV and HRV Measures." Backbone Publishing, 2004:59-65. IUMAB PDF →
- Bhat RK et al. "Correlation of EPI Parameters With Fasting Blood Sugar." J Evidence-Based CAM. 2016;22(3):441-448. PMC5871158 →
- Korotkov, K. "Review of EPI papers 2008–2018." Int J Complement Alt Med. 2018;11(6). DOI →
- IUMAB research database. iumab.club →
Share:
GDV and heart rate variability: what the correlation tells us
Find a Bio-Well scan near you: what to expect at your first session